Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- MASLD often goes unnoticed and is underestimated
Think tank for improving the supply situation
- DGPPN Congress
People at the center of care
- Lung cancer
Multidisciplinary teams in oncology
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- Seborrheic dermatitis in adults
Do not underestimate the symptom burden
- SGLT2 inhibitors
Clear, simple language improves patient safety
- Moderate to severe atopic dermatitis
Established and novel biologics – the therapeutic landscape is in flux
- Recognize CKD early and avoid dialysis